Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Psychotic major depression (PMD) is found to be a relatively common psychiatric condition that affects up to nearly 20% of patients with major depression. Previous studies by our group have shown rapid reversal of psychotic symptoms in some PMD patients treated with mifepristone, in addition to restoring a more normal afternoon cortisol release. The rationale for treating patients with PMD with a glucocorticosteroid receptor antagonist is further discussed. In total, 30 patients with PMD were treated with either 600 mg/day mifepristone or placebo for 8 days in a randomized double-blind manner. The Hamilton Depression Rating Scale (HDRS) and the Brief Psychiatric Rating Scale (BPRS) were administered at baseline and again after 8 days of treatment. Cortisol and ACTH were measured hourly from 1800 to 0900 at baseline and after 8 days of treatment. Significantly, more patients in the mifepristone group (seven of 15) showed a 50% or greater decline on the BPRS positive symptom subscale, an index of psychotic symptoms, as compared to the placebo group (two of 15). Patients who received mifepristone had lower HDRS and BPRS scores at study completion compared to those who received placebo, but these differences were not statistically significant. In addition, mifepristone significantly elevated cortisol and ACTH levels and steepened ascending slopes from 1800 to 0100 and from 0100 to 0900 as compared to placebo. Clinical and biological effects of mifepristone were comparable among males and females. Age was found to significantly and positively correlate with changes in cortisol and ACTH. These results suggest that short-term use of mifepristone may be effective in the treatment of PMD and may re-regulate the HPA axis. Additional blinded studies are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“4 double-blind [89-92] and 2 open-label trials [93, 94] suggested a significant reduction in psychotic symptoms, which was the primary outcome of these trials.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [91]
In the citing paper
“Of note, depressive symptoms were considered secondary outcomes, and these trials often failed to show a significant improvement compared to placebo.”
From The HPA Axis as Target for Depression (2024) · cites this paper as [91]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 3×
“…procedures included the Structured Clinical Interview for the DSM-IV (SCID; First et al, 1997), the 21-item Hamilton Depression Rating Scale (HDRS; Hamilton, 1980), the Brief Psychiatric Rating Scale (BPRS; Overall and Gorham, 1961), and clinical laboratory tests (complete blood count,…”
MethodThe Brief Psychiatric Rating Scale.
Overall, J. E., & Gorham, D. R. (1962) · Psychological Reports · doi:10.2466/pr0.1962.10.3.799 · Cited by 11,090 · cited 3×
“The Hamilton Depression Rating Scale (HDRS) and the Brief Psychiatric Rating Scale (BPRS) were administered at baseline and again after 8 days of treatment.”
MethodBrain corticosteroid receptor balance and homeostatic control
de Kloet, E. R. (1991) · Frontiers in Neuroendocrinology · Cited by 842
Disrupted 24-hour patterns of cortisol secretion in psychotic depression
Sachar, E. J. (1973) · Archives of General Psychiatry · doi:10.1001/archpsyc.1973.01750310011002 · Cited by 775 · cited 1×
“…they demonstrate excessive hypothalamic–pituitary–adrenal (HPA) axis activity, as evidenced by elevated urinary free cortisol levels (Kathol et al, 1989), elevated evening and night time cortisol levels (Sachar et al, 1973), and high rates of dexamethasone nonsuppression (Nelson and Davis, 1997).”
BackgroundLupien, S. J., Gillin, C. J., & Hauger, R. L. (1999) · Behavioral Neuroscience · doi:10.1037/0735-7044.113.3.420 · Cited by 561 · cited 1×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
ResultDecreased memory performance in healthy humans induced by stress-level cortisol treatment
Newcomer, J. W. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.6.527 · Cited by 546 · cited 1×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
ResultFunctional biology of intestinal goblet cells
Specian, R. D., & Oliver, M. G. (1991) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.1991.260.2.c183 · Cited by 467
The pharmacological treatment of delusional depression
(1985) · American Journal of Psychiatry · doi:10.1176/ajp.142.4.430 · Cited by 357
DST Studies in Psychotic Depression: A Meta-Analysis
Nelson, J. C., & Davis, J. M. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1497 · Cited by 356 · cited 2×
“Most notably, they demonstrate excessive hypothalamic–pituitary–adrenal (HPA) axis activity, as evidenced by elevated urinary free cortisol levels (Kathol et al, 1989), elevated evening and night time cortisol levels (Sachar et al, 1973), and high rates of dexamethasone nonsuppression (Nelson and Davis, 1997).”
BackgroundAn open label trial of C-1073 (mifepristone) for psychotic major depression*
Belanoff, J. K., Rothschild, A. J., Cassidy, F., DeBattista, C., Baulieu, E.-E., Schold, C., & Schatzberg, A. F. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01432-4 · Cited by 320
Self-citationYoung, A. H., Gallagher, P., Watson, S., Del-Estal, D., Owen, B. M., & Nicol Ferrier, I. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300471 · Cited by 318 · cited 2×
“…studies by our group have shown significant reduction of psychotic symptoms in some patients treated with mifepristone (Belanoff et al, 2001, 2002), and a study by Young et al (2004) reported that the drug rapidly resulted in improved cognition (verbal memory) in nonpsychotic bipolar depressives.”
BackgroundPrevalence of Depressive Episodes With Psychotic Features in the General Population
Ohayon, M. M., & Schatzberg, A. F. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1855 · Cited by 290 · cited 2×
“In this latter study, unipolar major depression with psychotic features was found to affect four in 1000 individuals (Ohayon and Schatzberg, 2002).”
BackgroundSelf-citationRapid Reversal of Psychotic Depression Using Mifepristone
Belanoff, J. K., Flores, B. H., Kalezhan, M., Sund, B., & Schatzberg, A. F. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00009 · Cited by 282 · cited 4×
“It is noteworthy that in a prior 4-day crossover study (Belanoff et al, 2001), subjects demonstrated peak afternoon (1300–1600) cortisol levels of as high as approximately 60 mg/dl in as little as 4 days of treatment.”
BackgroundResultInfluentialSelf-citationA corticosteroid/dopamine hypothesis for psychotic depression and related states
Schatzberg, A. F., Rothschild, A. J., Langlais, P. J., Bird, E. D., & Cole, J. O. (1985) · Journal of Psychiatric Research · doi:10.1016/0022-3956(85)90068-8 · Cited by 244 · cited 1×
“In addition, a number of years ago, we hypothesized that the psychotic features of PMD were due to excessive glucocorticoid activity (Schatzberg et al, 1985).”
BackgroundSelf-citationThe Validity of Major Depression With Psychotic Features Based on a Community Study
Johnson, J. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810360039006 · Cited by 232 · cited 1×
“Johnson et al (1991) reported that 14.7% of subjects who met criteria for major depression had a history of psychotic features.”
BackgroundInfluentialMifepristone (RU 486) -- A Modulator of Progestin and Glucocorticoid Action
Wood, A. J. J., Spitz, I. M., & Bardin, C. W. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308053290607 · Cited by 221 · cited 1×
“Mifepristone in vivo is a competitive inhibitor of GR but is inactive at MR (Mahajan and London, 1997; Spitz and Bardin, 1993).”
BackgroundGesing, A., Bilang-Bleuel, A., Droste, S. K., Linthorst, A. C. E., Holsboer, F., & Reul, J. M. H. M. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-13-04822.2001 · Cited by 210 · cited 2×
“This could result in elevated cortisol levels since MR in the hippocampus is thought to exert an inhibitory effect on the HPA axis via projections to the hypothalamus (Oitzl et al, 1995; Gesing et al, 2001; Young et al, 2003).”
BackgroundNeuropsychological Deficits in Psychotic Versus Nonpsychotic Major Depression and No Mental Illness
Schatzberg, A. F., Posener, J. A., DeBattista, C., Kalehzan, B. M., Rothschild, A. J., & Shear, P. K. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.7.1095 · Cited by 210 · cited 2×
“…from nonpsychotic major depression (NPMD), as evidenced by significant differences on a number of different dimensions: neuropsychological testing (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004), response to treatment (Spiker et al, 1985), and morbidity and mortality (Rothschild,…”
BackgroundResultSelf-citationMineralocorticoid Receptor Function in Major Depression
Young, E. A., Lopez, J. F., Murphy-Weinberg, V., Watson, S. J., & Akil, H. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.24 · Cited by 204 · cited 5×
“MR binds with high affinity to cortisol and has been shown to be involved in the regulation of both the peak and nadir of the circadian rhythm, respectively, the morning and evening in humans (Young et al, 2003; Otte et al, 2003; Kalman and Spencer, 2002).”
BackgroundInfluentialOitzl, M. S., van Haarst, A. D., Sutanto, W., & de Kloet, E. R. (1995) · Psychoneuroendocrinology · doi:10.1016/0306-4530(95)00003-7 · Cited by 169 · cited 2×
“This could result in elevated cortisol levels since MR in the hippocampus is thought to exert an inhibitory effect on the HPA axis via projections to the hypothalamus (Oitzl et al, 1995; Gesing et al, 2001; Young et al, 2003).”
BackgroundSpencer, R. L. (1998) · Endocrinology · doi:10.1210/en.139.6.2718 · Cited by 169
Mifepristone (RU486): A review
Mahajan, D. K., & London, S. N. (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)00189-1 · Cited by 164 · cited 1×
“Mifepristone in vivo is a competitive inhibitor of GR but is inactive at MR (Mahajan and London, 1997; Spitz and Bardin, 1993).”
BackgroundTrapp, T., & Holsboer, F. (1996) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(96)81590-2 · Cited by 162 · cited 4×
“When they bind with cortisol, they dimerize and translocate to the cell’s nucleus (Trapp and Holsboer, 1996).”
BackgroundInfluentialGluco- and antimineralocorticoid effects on human sleep: a role of central corticosteroid receptors
Born, J., DeKloet, E. R., Wenz, H., Kern, W., & Fehm, H. L. (1991) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1991.260.2.e183 · Cited by 161 · cited 1×
“By blocking GR, mifepristone immediately reduces this receptor’s transmission but it also raises circulating cortisol by blocking cortisol’s feedback mechanism (Born et al, 1991).”
BackgroundPariante, C. M., Makoff, A., Lovestone, S., Feroli, S., Heyden, A., Miller, A. H., & Kerwin, R. W. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704368 · Cited by 159 · cited 1×
“As such, mifepristone could sequester cortisol in the brain and consequently play a role in reregulating the axis by flooding MR. Pariante et al (2001, 2003) have argued elevated peripheral cortisol could reflect low central cortisol in brain.”
BackgroundNeuropsychological Dysfunction in Antipsychotic-Naive First-Episode Unipolar Psychotic Depression
Hill, S. K., Keshavan, M. S., Thase, M. E., & Sweeney, J. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.6.996 · Cited by 146 · cited 2×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
BackgroundResultPsychotic Depression and Mortality
Vythilingam, M., Chen, J., Bremner, J. D., Mazure, C. M., Maciejewski, P. K., & Nelson, J. C. (2003) · American Journal of Psychiatry · doi:10.1176/appi.ajp.160.3.574 · Cited by 141 · cited 1×
“…as evidenced by significant differences on a number of different dimensions: neuropsychological testing (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004), response to treatment (Spiker et al, 1985), and morbidity and mortality (Rothschild, 2003; Vythilingam et al, 2003).”
BackgroundThe clinical and neuroendocrine features of psychotic depression.
CORYELL, W., PFOHL, B., & ZIMMERMAN, M. (1984) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198409000-00002 · Cited by 135 · cited 1×
“Similarly, in a study of consecutively admitted depressed patients, approximately 25% were psychotic (Coryell et al, 1984).”
ResultAging and cortisol resistance to suppression by dexamethasone: A positive correlation
Oxenkrug, G. F., Pomara, N., McIntyre, I. M., Branconnier, R. J., Stanley, M., & Gershon, S. (1983) · Psychiatry Research · doi:10.1016/0165-1781(83)90111-7 · Cited by 127 · cited 1×
“Studies by Oxenkrug et al (1983) and Rosenbaum et al (1984) found positive correlations between age and postdexamethasone cortisol concentration among healthy subjects.”
BackgroundDeBattista, C., Posener, J. A., Kalehzan, B. M., & Schatzberg, A. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.8.1334 · Cited by 113 · cited 1×
“Moreover, we have observed that although cortisol infusions improve mood in nonpsychotic depression (DeBattista et al, 2000), cortisol infusions in PMD had no positive effects (Schatzberg, unpublished data).”
BackgroundSelf-citationChallenges in the treatment of depression with psychotic features
Rothschild, A. J. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01747-x · Cited by 112 · cited 2×
“There are considerable data suggesting that PMD is a distinct syndrome from nonpsychotic major depression (NPMD), as evidenced by significant differences on a number of different dimensions: neuropsychological testing (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004), response to treatment (Spiker et al,…”
BackgroundThe role of the efflux transporter P-glycoprotein in brain penetration of prednisolone
Karssen, A., Meijer, O., van der Sandt, I., De Boer, A., De Lange, E., & De Kloet, E. (2002) · Journal of Endocrinology · doi:10.1677/joe.0.1750251 · Cited by 110 · cited 2×
“Last, there may be different effects on specific glucocorticoidsFfor example, a greater effect on retaining corticosterone than cortisol (Karssen et al, 2002).”
BackgroundFleming, S. K., Blasey, C., & Schatzberg, A. F. (2004) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(03)00100-6 · Cited by 104 · cited 2×
“Administration of glucocorticoids to healthy controls (Lupien et al, 1999; Newcomer et al, 1999) results in cognitive deficits similar to those seen with PMD (Schatzberg et al, 2000; Fleming et al, 2004; Hill et al, 2004).”
BackgroundResultSelf-citationKalman, B. A., & Spencer, R. L. (2002) · Endocrinology · doi:10.1210/en.2002-220375 · Cited by 90 · cited 2×
“…USA, Tel: + 1 650 498 7378, Fax: + 1 650 723 8331, E-mail: bflores@stanford.edu Neuropsychopharmacology (2006) 31, 628–636 & 2006 Nature Publishing Group All rights reserved 0893-133X/06 $30.00 www.neuropsychopharmacology.org Spencer et al, 1998; Trapp and Holsboer, 1996; Kalman and Spencer, 2002).”
BackgroundInfluentialPariante, C. M., Kim, R. B., Makoff, A., & Kerwin, R. W. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705357 · Cited by 89 · cited 1×
“As such, mifepristone could sequester cortisol in the brain and consequently play a role in reregulating the axis by flooding MR. Pariante et al (2001, 2003) have argued elevated peripheral cortisol could reflect low central cortisol in brain.”
BackgroundSimpson, G. M., Sheshai, A. E., Loza, N., Kingsbury, S. J., Fayek, M., Rady, A., & Fawzy, W. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0509 · Cited by 63 · cited 1×
“This trend toward continuing amelioration of symptoms of psychosis beyond 8 days of treatment with mifepristone is consistent with recent published findings by Simpson et al (2005).”
Result(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.12.1550 · Cited by 61 · cited 1×
“Studies by Oxenkrug et al (1983) and Rosenbaum et al (1984) found positive correlations between age and postdexamethasone cortisol concentration among healthy subjects.”
BackgroundSelf-citationOtte, C., Jahn, H., Yassouridis, A., Arlt, J., Stober, N., Maass, P., Wiedemann, K., & Kellner, M. B. (2003) · Life Sciences · doi:10.1016/s0024-3205(03)00513-7 · Cited by 56 · cited 2×
“…activity is in large part controlled by the balance between mineralocorticoid receptors (MR) and glucocorticoid receptors (GR) (Young et al, 2003; Otte et al, 2003; Online publication: 1 August 2005 at http://www.acnp.org/citations/ Npp080105050013/default.pdf Received 7 January 2005; revised 1…”
BackgroundDirect comparison of urinary free cortisol excretion in patients with depression and panic disorder
Kathol, R. G., Anton, R. F., Noyes, R., & Gehris, T. L. (1989) · Biological Psychiatry · doi:10.1016/0006-3223(89)90267-9 · Cited by 43 · cited 1×
“Most notably, they demonstrate excessive hypothalamic–pituitary–adrenal (HPA) axis activity, as evidenced by elevated urinary free cortisol levels (Kathol et al, 1989), elevated evening and night time cortisol levels (Sachar et al, 1973), and high rates of dexamethasone nonsuppression (Nelson and…”
BackgroundAntiglucocorticoid treatment disrupts endocrine cycle and nocturnal sleep pattern
Wiedemann, K., Lauer, C. J., Loycke, A., Pollmächer, T., Durst, P., Macher, J. P., & Holsboer, F. (1992) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02191963 · Cited by 32 · cited 1×
“An earlier study in a healthy control reported 400 mg/day of mifepristone increased cortisol and ACTH levels in the very early morning but not during the evening hours (Wiedemann et al, 1992).”
BackgroundFink, M., & Nemeroff, C. B. (1989) · PubMed · Cited by 23
Research works printed but not linked: 1
- First MB, Spitzer RL, Gibbon M, Williams JBW (1997). Structured Clinical Interview for DSM IV-TR Axis I Disorders—Patient Edition (SCID-I/P, 2/2001 revision). American Psychiatric Press, Inc.: Washington, DC.
Cited by
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Belmaker, R. H., & Agam, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra073096 · Cited by 2,166
The HPA axis in major depression: classical theories and new developments
Pariante, C. M., & Lightman, S. L. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.06.006 · Cited by 2,009
New approaches to antidepressant drug discovery: beyond monoamines
Berton, O., & Nestler, E. J. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1846 · Cited by 1,589
Anderson, I., Ferrier, I., Baldwin, R., Cowen, P., Howard, L., Lewis, G., Matthews, K., McAllister-Williams, R., Peveler, R., Scott, J., et al. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107088441 · Cited by 908
Metadata
- Authors
- Flores, B. H., Kenna, H., Keller, J., Solvason, H. B., & Schatzberg, A. F.
- Affiliations
- Stanford University (US)
- Stanford Medicine (US)
- Corresponding author
- Flores, Benjamin H
- Venue
- Neuropsychopharmacology
- Published
- 2005-09-14
- Volume
- 31
- Issue
- 3
- Pages
- 628-636
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2081535802
- Cited by
- 203
- References
- 41
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 4 · 2021: 5 · 2020: 3 · 2019: 4 · 2018: 12 · 2017: 9 · 2016: 9 · 2015: 10 · 2014: 12 · 2013: 13 · 2012: 11
- FWCI
- 11.70
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (MH50604)
- National Institute of Mental Health (R0-1MH50604, MH-47573, R01MH050604, R01 MH 47573, R01MH047573, T32MH019938)
- National Center for Research Resources (M01RR000070)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- mifepristone, psychotic depression, glucocorticoid receptor antagonist, hypothalamic-pituitary-adrenal axis, cortisol, ACTH, depression treatment
- MeSH terms
- Adrenocorticotropic Hormone, Adult, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Hormone Antagonists, Humans, Hydrocortisone, Hypothalamo-Hypophyseal System, Male, Psychiatric Status Rating Scales, Receptors, Glucocorticoid, Sex Characteristics, Mifepristone, Linear Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.